新型口服抗凝药物在急性冠状动脉综合征中的应用
摘要
部分急性冠状动脉综合征（acute coronary syndrome，ACS）患者在事件后的数周和数个月内仍有可能再次发生血栓事件，因此抑制凝血酶生成和活化是ACS治疗的重要组成部分。虽然普通肝素、低分子量肝素、磺达肝癸钠和比伐芦定用于治疗ACS均可获益，但由于需胃肠道外给药因而限制了出院后患者的长期使用。
出处
《中国医师进修杂志》
2014年第34期71-73,共3页
Chinese Journal of Postgraduates of Medicine
参考文献15
-
1Sorensen R, Hansen ML, Abildstrom SZ, et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data[J]. Lancet,2009,374(9706) : 1967-1974.
-
2Costopoulos C, Niespialowska-Steuden M, Kukreja N, et al. Novel oral anticoagulants in acute coronary syndrome [J]. Int J Cardiol, 2013,167(6) :2449-2455.
-
3APPRAISE Steering Committee and Investigators, Alexander JH, Becker RC, et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trim [J]. Circulation, 2009,119(22) :2877-2885.
-
4Alexander JH, Lopes RD, James S, et al. Apixaban with antiplatelet therapy after acute coronary syndrome [J]. N Engl J Med,2011,365(8) : 699-708.
-
5Wong H, Nunokawa N, Song JC, et al. Rivaroxaban: a direct factor Xa inhibitor for VTE prophylaxis in patients undergoing total knee or hip replacement surgery [J]. Formulary,2009,44 (7) : 226-236.
-
6EINSTEIN Investigators, Bauersachs R, Berkowitz SD, et al. Oral rivaroxaban for symptomatic venous thromboembolism[ J]. N Engl J Med, 2010,363 (26) : 2499-2510.
-
7Patel MR, Mahaffey KW, Garg J,et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation [J]. N Engl J Med, 2011,365(10) : 883-891.
-
8Mega JL, Braunwald E, Mohanavelu S,et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS- TIMI 46) : a randomised, double-blind, phase II trial [ J ]. Lancet, 2009,374(9683 ) :29-38.
-
9Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome [J]. N Engl J Med, 2012,366( 1 ) :9-19.
-
10Heeringa M, Groenendaal D, Strabach G, et al. The pharmacokinetics of YM150, an oral direct factor Xa inhibitor, are not affected to a clinically relevant degree by strong inhibition or induction of CYP3A4 and P-gp [ J ]. J Thromb Hemost, 2011,9 Suppl 2: S359-360.
-
1吴楠,顾晴,关玉霞,李宾宾.心房颤动患者华法林抗凝治疗的管理现状[J].中华护理杂志,2014,49(3):337-340. 被引量：46
-
2刘英明,杨晔,李田昌.口服抗凝药物预防心房颤动患者脑卒中的研究进展[J].中国心血管杂志,2012,17(3):231-233. 被引量：7
-
3赵梦华,石建平,刘吉祥.心房纤颤并发冠状动脉疾病患者的抗栓治疗研究进展[J].医学研究杂志,2013,42(5):20-22. 被引量：1
-
4张学义,潘维恩,王乃震,牛晓棠.CHA2DS2-VASc评分系统在房颤患者健康管理中的应用[J].中国卫生产业,2013,10(6):82-82.
-
5姚璐,张薇,田国祥,夏常泉,武云涛,王晓兵,李娟.达比加群酯应用于高龄老年非瓣膜性心房纤颤患者中的安全性评价[J].中国循证心血管医学杂志,2016,8(5):547-549. 被引量：16
-
6赵明磊,毕齐.心房颤动合并急性冠状动脉综合征患者的抗栓治疗研究进展[J].心肺血管病杂志,2016,35(12):992-995. 被引量：1
-
7万槐斌,杨艳敏.新型口服抗凝药物与急性冠状动脉综合征的二级预防[J].中华心血管病杂志,2015,43(5):455-458. 被引量：3
-
8Yusu.,S,许俊堂.冠状动脉疾病的口服抗凝药物治疗：汇总分析[J].美国医学会杂志（中文版）,2000,19(6):304-312.
-
9魏荣,孙秀芹,初兰珍,吕艳,刘广存.社区护理干预对高血压患者遵医行为的影响[J].山东医药,2003,43(20):54-55. 被引量：1
-
10史立婷.浅谈老年高血压患者的出院指导[J].工企医刊,2011,24(6):38-39.
